Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. (Nasdaq: NAUT) entered the public markets through a business combination with Arya Sciences Acquisition Corp III, a blank-check vehicle sponsored by Perceptive Advisors that completed its IPO in 2020. The company filed an S-1 registration statement on July 22, 2021, in connection with its listing following the completed de-SPAC transaction. Nautilus operates in the life sciences sector, specifically proteomics, developing a single-molecule protein sequencing platform designed to enable large-scale protein analysis for drug discovery and clinical research applications. Sign up on SpacDesk for full data, filings, and deal analytics on NAUT and the broader de-SPAC universe.